Novavax Company Profile (NASDAQ:NVAX)

About Novavax

Novavax logoNovavax, Inc. (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. Its product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). Its lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: NVAX
  • CUSIP: 67000210
Key Metrics:
  • Previous Close: $2.35
  • 50 Day Moving Average: $6.23
  • 200 Day Moving Average: $6.11
  • 52-Week Range: $1.16 - $9.23
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.67
  • P/E Growth: 0.00
  • Market Cap: $652.71M
  • Outstanding Shares: 270,834,000
  • Beta: 1.4
  • Net Margins: -1,405.84%
  • Return on Equity: -112.45%
  • Return on Assets: -56.29%
  • Debt-to-Equity Ratio: 2.87%
  • Current Ratio: 5.13%
  • Quick Ratio: 5.13%
Additional Links:
Companies Related to Novavax:

Analyst Ratings

Consensus Ratings for Novavax (NASDAQ:NVAX) (?)
Ratings Breakdown: 6 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: $7.02 (198.78% upside)

Analysts' Ratings History for Novavax (NASDAQ:NVAX)
DateFirmActionRatingPrice TargetDetails
9/20/2016Chardan CapitalLower Price TargetNeutral$5.75 -> $1.50View Rating Details
9/16/2016S&P Equity ResearchLower Price Target$1.44 -> $1.17View Rating Details
9/16/2016Citigroup Inc.DowngradeBuy -> Neutral$12.00 -> $1.50View Rating Details
9/16/2016JPMorgan Chase & Co.DowngradeOverweight -> NeutralView Rating Details
9/16/2016Piper Jaffray Cos.DowngradeOverweight -> Neutral$14.00 -> $1.00View Rating Details
9/16/2016Ladenburg ThalmannDowngradeBuy -> NeutralView Rating Details
9/16/2016FBR & CoLower Price TargetOutperform$17.00 -> $12.00View Rating Details
9/16/2016WedbushDowngradeOutperform -> Neutral$14.00 -> $2.00View Rating Details
8/29/2016GuggenheimReiterated RatingBuy$25.00View Rating Details
4/7/2015Janney Montgomery ScottReiterated Rating$12.00View Rating Details
2/12/2015GMP SecuritiesInitiated CoveragePositiveView Rating Details
(Data available from 9/27/2014 forward)


Earnings History for Novavax (NASDAQ:NVAX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2016Q216($0.25)($0.29)$8.03 million$2.50 millionViewListenView Earnings Details
5/4/2016Q1($0.27)($0.29)$10.39 million$4.20 millionViewListenView Earnings Details
2/29/2016Q415($0.14)($0.29)$8.07 million$5.90 millionViewListenView Earnings Details
11/9/2015Q315($0.09)($0.12)$10.59 million$6.50 millionViewN/AView Earnings Details
8/10/2015Q215($0.09)($0.08)$9.90 million$14.00 millionViewListenView Earnings Details
5/7/2015Q115($0.11)($0.10)$9.70 million$9.88 millionViewN/AView Earnings Details
2/26/2015Q4 14($0.08)($0.13)$9.60 million$6.70 millionViewN/AView Earnings Details
11/5/2014Q314($0.07)($0.08)$9.20 million$8.20 millionViewN/AView Earnings Details
8/6/2014Q214($0.07)($0.08)$8.74 million$8.26 millionViewN/AView Earnings Details
5/7/2014Q114($0.07)($0.07)$3.80 million$7.50 millionViewN/AView Earnings Details
3/10/2014Q413($0.08)($0.07)$6.22 million$8.70 millionViewN/AView Earnings Details
11/7/2013Q313($0.06)($0.09)$4.56 million$4.80 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.06)($0.08)$4.45 million$3.50 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.06)($0.07)$5.54 million$3.80 millionViewN/AView Earnings Details
3/1/2013Q4 2012($0.04)($0.06)$5.85 million$4.57 millionViewN/AView Earnings Details
11/2/2012Q312($0.05)($0.05)$7.59 million$5.80 millionViewN/AView Earnings Details
8/3/2012($0.07)($0.05)ViewN/AView Earnings Details
5/4/2012($0.04)($0.06)ViewN/AView Earnings Details
3/9/2012($0.04)($0.03)ViewN/AView Earnings Details
11/4/2011($0.06)($0.03)ViewN/AView Earnings Details
8/5/2011($0.08)($0.04)ViewN/AView Earnings Details
5/9/2011($0.07)($0.07)ViewN/AView Earnings Details
3/28/2011($0.09)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Novavax (NASDAQ:NVAX)
Current Year EPS Consensus Estimate: $-1.09 EPS
Next Year EPS Consensus Estimate: $-0.88 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.27)($0.13)($0.22)
Q2 20163($0.28)($0.13)($0.19)
Q3 20162($0.27)($0.24)($0.26)
Q4 20162($0.26)($0.24)($0.25)
Q1 20171($0.25)($0.25)($0.25)
Q2 20171($0.25)($0.25)($0.25)
Q3 20171($0.24)($0.24)($0.24)
Q4 20171($0.25)($0.25)($0.25)
(Data provided by Zacks Investment Research)


Dividend History for Novavax (NASDAQ:NVAX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Novavax (NASDAQ:NVAX)
Insider Ownership Percentage: 3.50%
Institutional Ownership Percentage: 79.84%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/22/2016John TrizzinoSVPBuy46,000$2.17$99,820.00View SEC Filing  
9/21/2016Gregory M GlennInsiderBuy1,000$1.65$1,650.00View SEC Filing  
9/21/2016Michael A Mcmanus JrDirectorBuy30,000$1.61$48,300.00View SEC Filing  
9/20/2016Gail BoudreauxDirectorBuy100,000$1.45$145,000.00View SEC Filing  
7/31/2016Barclay A. PhillipsCFOBuy422$4.29$1,810.38View SEC Filing  
6/6/2016Gary C EvansDirectorSell18,998$6.50$123,487.00View SEC Filing  
5/24/2016Gary C EvansDirectorSell50,000$5.41$270,500.00View SEC Filing  
3/31/2016Stanley C ErckCEOSell424,778$5.19$2,204,597.82View SEC Filing  
1/31/2016Barclay A. PhillipsCFOBuy405$4.38$1,773.90View SEC Filing  
1/31/2016Gregory M. GlennSVPBuy2,369$4.38$10,376.22View SEC Filing  
1/31/2016Stanley C. ErckCEOBuy2,072$4.38$9,075.36View SEC Filing  
12/16/2015John A Herrmann IIISVPSell27,945$8.64$241,444.80View SEC Filing  
8/24/2015Gary C EvansDirectorSell20,000$11.24$224,800.00View SEC Filing  
8/20/2015Barclay A. PhillipsCFOSell28,656$13.06$374,247.36View SEC Filing  
8/18/2015Gregory M. GlennSVPSell15,000$13.52$202,800.00View SEC Filing  
8/13/2015Gary C EvansDirectorSell6,002$13.56$81,387.12View SEC Filing  
6/18/2015James F YoungDirectorSell50,000$9.47$473,500.00View SEC Filing  
6/17/2015Rajiv I ModiDirectorSell433,053$9.01$3,901,807.53View SEC Filing  
6/11/2015Rajiv I ModiDirectorSell11,185$9.00$100,665.00View SEC Filing  
6/10/2015Rajiv I ModiDirectorSell551,081$8.97$4,943,196.57View SEC Filing  
6/9/2015Rajiv I ModiDirectorSell47,531$8.93$424,451.83View SEC Filing  
6/8/2015Rajiv I ModiDirectorSell206,175$8.93$1,841,142.75View SEC Filing  
6/4/2015Rajiv I ModiDirectorSell504,681$8.92$4,501,754.52View SEC Filing  
6/1/2015Rajiv I ModiDirectorSell3,500,000$8.74$30,590,000.00View SEC Filing  
1/31/2015Barclay A PhillipsCFOBuy8,388$2.28$19,124.64View SEC Filing  
1/31/2015John TrizzinoSVPBuy6,611$3.63$23,997.93View SEC Filing  
1/31/2015Stanley C ErckCEOBuy6,122$2.28$13,958.16View SEC Filing  
12/16/2014Gary C EvansDirectorSell46,701$5.72$267,129.72View SEC Filing  
12/12/2014Gary C EvansDirectorSell30,000$5.77$173,100.00View SEC Filing  
11/20/2014Rajiv I ModiDirectorSell518,889$5.02$2,604,822.78View SEC Filing  
11/18/2014Rajiv I ModiDirectorSell1,481,111$5.00$7,405,555.00View SEC Filing  
10/3/2014Barclay A PhillipsCFOBuy5,000$4.11$20,550.00View SEC Filing  
10/3/2014Timothy Jon HahnSVPBuy2,500$4.05$10,125.00View SEC Filing  
9/26/2014Gregory M GlennSVPSell16,809$4.16$69,925.44View SEC Filing  
9/25/2014Timothy Jon HahnSVPBuy9,000$4.17$37,530.00View SEC Filing  
7/31/2014Barclay A PhillipsCFOBuy8,788$2.28$20,036.64View SEC Filing  
7/31/2014Russell P WilsonSVPBuy4,989$2.28$11,374.92View SEC Filing  
7/31/2014Stanley C ErckCEOBuy6,788$2.28$15,476.64View SEC Filing  
6/17/2014John TrizzinoSVPBuy5,500$4.51$24,805.00View SEC Filing  
6/16/2014John TrizzinoSVPBuy16,500$4.51$74,415.00View SEC Filing  
3/25/2014Barclay PhillipsCFOBuy5,000$4.25$21,250.00View SEC Filing  
3/25/2014Richard DouglasDirectorBuy50,000$4.33$216,500.00View SEC Filing  
3/25/2014Stanley ErckCEOBuy10,000$4.27$42,700.00View SEC Filing  
3/21/2014Pharmaceuticals Ltd Cadilamajor shareholderSell3,000,000$4.95$14,850,000.00View SEC Filing  
1/31/2014Barclay PhillipsCFOBuy9,868$2.29$22,597.72View SEC Filing  
1/31/2014Stanley ErckCEOBuy11,868$2.29$27,177.72View SEC Filing  
1/31/2014Timothy Jon HahnSVPBuy9,416$2.29$21,562.64View SEC Filing  
6/12/2013Richard DouglasDirectorBuy50,000$1.90$95,000.00View SEC Filing  
6/10/2013Timothy Jon HahnSVPBuy21,000$1.88$39,480.00View SEC Filing  
6/7/2013Gregory M GlennInsiderBuy2,000$1.92$3,840.00View SEC Filing  
6/6/2013James F YoungDirectorBuy100,000$1.91$191,000.00View SEC Filing  
3/11/2013James F YoungDirectorBuy100,000$2.03$203,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Novavax (NASDAQ:NVAX)
News IconAnalysts Valuations For Two Stocks: Novavax, Inc. (NASDAQ:NVAX), Investors Bancorp, Inc. (NASDAQ:ISBC) - The Voice Registrar (NASDAQ:NVAX) - September 25 at 5:49 PM
News IconTrader's Buzzer - Novavax, Inc.'s (NVAX) - Hot Stocks Point (NASDAQ:NVAX) - September 25 at 5:49 PM logoInsiders at Novavax Inc. (NASDAQ:NVAX) Buy Shares on the Dip; Four Other Companies See Notable Insider ... - Insider Monkey (blog) (NASDAQ:NVAX) - September 24 at 5:54 PM logoExclusive: Novavax CEO Responds To Recent Insider Buys (NASDAQ:NVAX) - September 23 at 3:32 PM logoCan Novavax, Inc. Salvage Anything From Its Recent Disaster? (NASDAQ:NVAX) - September 23 at 11:59 AM
News IconInvestment Analysts' Weekly Ratings Changes for Novavax (NVAX) (NASDAQ:NVAX) - September 23 at 11:10 AM logoETF’s with exposure to Novavax, Inc. : September 23, 2016 (NASDAQ:NVAX) - September 23 at 11:10 AM
News IconNovavax, Inc.'s (NVAX) (NASDAQ:NVAX) - September 22 at 6:09 PM logoNovavax, Inc. (NVAX) Options Hot After Director Doubles Stake (NASDAQ:NVAX) - September 22 at 6:09 PM logoAnalyst on Novavax's dismal drug trial: 'I was as surprised as anyone' (NASDAQ:NVAX) - September 22 at 6:09 PM
News IconInsiders at Novavax Inc. (NASDAQ:NVAX) Buy Shares on the Dip; Four Other Companies See Notable Insider Transactions (NASDAQ:NVAX) - September 22 at 3:12 PM logoNVAX Stock: Novavax Attempts to Claw Its Way Back From the Pits (NASDAQ:NVAX) - September 22 at 11:51 AM
News IconGrowth Analysis of Novavax, Inc. (NASDAQ:NVAX) - Newburgh Press (NASDAQ:NVAX) - September 21 at 6:08 PM
News IconNovavax, Inc. (NVAX) Upgrades/Downgrades review - Newburgh Press (NASDAQ:NVAX) - September 21 at 6:08 PM
News IconBiotech Stocks Worth a Closer Look: Novavax, Inc. (NASDAQ:NVAX), Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - The Voice Registrar (NASDAQ:NVAX) - September 21 at 6:08 PM logoChardan Slashes Price Target for Novavax, Inc. (NVAX); Offers Commentary on Recent Phase 3 Trial Failure - Smarter Analyst (NASDAQ:NVAX) - September 21 at 6:08 PM
News IconNovavax Inc. (NVAX) Lowered to Neutral at Wedbush (NASDAQ:NVAX) - September 21 at 10:37 AM
News IconNovavax, Inc. 925.6% Potential Upside Now Implied by FBR & Co (NASDAQ:NVAX) - September 21 at 10:37 AM
News IconNovavax Inc. (NVAX) Lowered to "Neutral" at Piper Jaffray Cos (NASDAQ:NVAX) - September 21 at 10:37 AM logoChardan Slashes Price Target for Novavax, Inc. (NVAX); Offers Commentary on Recent Phase 3 Trial Failure (NASDAQ:NVAX) - September 21 at 10:37 AM logoGaithersburg biotech reels after disappointing clinical trial results (NASDAQ:NVAX) - September 21 at 10:37 AM logoNOVAVAX INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:NVAX) - September 21 at 10:37 AM
News IconBiotech Stocks Worth Chasing: Idera Pharmaceuticals, Inc. (IDRA), Novavax, Inc. (NVAX) - The Independent Republic (NASDAQ:NVAX) - September 20 at 11:46 AM
News IconBiotech Stocks Worth a Closer Look: Novavax, Inc. (NASDAQ:NVAX), Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) - The Voice Registrar (NASDAQ:NVAX) - September 19 at 6:30 PM logoThe Biggest Pharma Stock Blowups Of 2016 (NASDAQ:NVAX) - September 19 at 3:49 PM
News IconHere’s Why Novavax Inc. (NVAX), United States Steel Corporation (X) and Three Other Stocks Are Gaining Ground on Monday (NASDAQ:NVAX) - September 19 at 3:13 PM logoThe Search For Silver Linings In The Cloud Of Negative Novavax News (NASDAQ:NVAX) - September 19 at 12:47 PM logoNovavax Inc. (NVAX) Plunged To A New Low After Phase 3 Studies Failed (NASDAQ:NVAX) - September 19 at 10:58 AM logoNovavax, Inc. breached its 50 day moving average in a Bearish Manner : NVAX-US : September 19, 2016 (NASDAQ:NVAX) - September 19 at 10:58 AM logoCompany News for September 19, 2016 (NASDAQ:NVAX) - September 19 at 10:58 AM logo4 Companies That Destroyed Shareholders Last Week (NASDAQ:NVAX) - September 18 at 10:46 AM logoWedbush Answers 'So, Now What?' For Novavax Shareholders (NASDAQ:NVAX) - September 17 at 6:02 PM logoUnderlying Risks in Speculative Biotechs; Trump Speaks, Bonds Slide : Best of Kass (NASDAQ:NVAX) - September 17 at 10:55 AM logo[$$] Overheard: Novavax Has a Bad Reaction (NASDAQ:NVAX) - September 17 at 10:55 AM logoWhy Novavax, Range Resources, and Deutsche Bank Slumped Today (NASDAQ:NVAX) - September 16 at 7:12 PM logoFBR Bullish On Novavax, Inc. (NVAX); Pullback Represents Strong Buying Opportunity (NASDAQ:NVAX) - September 16 at 6:16 PM logoFailure in Phase 3 Tanks Novavax's Stock (NVAX) (NASDAQ:NVAX) - September 16 at 6:16 PM logoNovavax is down 80%. Here’s why it’s been really hard to develop a RSV vaccine (NASDAQ:NVAX) - September 16 at 2:43 PM
News IconIs This the Ultimate Implosion of Novavax? (NASDAQ:NVAX) - September 16 at 11:54 AM logoWhy Novavax, Inc. Stock Just Imploded (NASDAQ:NVAX) - September 16 at 11:54 AM logoLadenburg Says No Need For Novavax To Rerun Failed Drug Study (NASDAQ:NVAX) - September 16 at 10:00 AM logoJP Morgan Downgrades Rating On Novavax, Inc. (NVAX) (NASDAQ:NVAX) - September 16 at 10:00 AM logoWhy Novavax (NVAX) Stock Plunged 83% in After-Hours Trading (NASDAQ:NVAX) - September 16 at 10:00 AM logoAnalyst Downgrades: Citigroup Inc, Novavax, Inc., and Oracle Corporation (NASDAQ:NVAX) - September 16 at 10:00 AM logoNovavax Inc. (NVAX) Is Plunging After Phase 3 Study Fails (NASDAQ:NVAX) - September 16 at 10:00 AM logoCompany Update (NASDAQ:NVAX): Novavax, Inc. Announces Topline RSV F Vaccine Data from Two Clinical Trials in Older Adults (NASDAQ:NVAX) - September 16 at 10:00 AM logoNovavax downgraded by Wedbush (NASDAQ:NVAX) - September 16 at 10:00 AM logoNovovax downgraded at JP Morgan and Wedbush on disappointing late-stage trial results (NASDAQ:NVAX) - September 16 at 10:00 AM logoTop Analyst Upgrades and Downgrades: Citigroup, Enterprise Products, GoPro, Lululemon, Novavax and More (NASDAQ:NVAX) - September 16 at 10:00 AM logoNovavax (NVAX) Stock Tumbles on Vaccine Trial Failure, Ratings Downgrades (NASDAQ:NVAX) - September 16 at 10:00 AM


Novavax (NASDAQ:NVAX) Chart for Tuesday, September, 27, 2016

Last Updated on 9/27/2016 by Staff